Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214877 | 0.95 | CYP4F2 (0.54) | CYP4F2CYP4A11KMT2AALDH1A1GAA | |
| SCHEMBL4113212 | 0.85 | CYP4F2 (0.76) | CYP4F2CYP4A11KMT2AALDH1A1GAA | |
| SCHEMBL14404459 | 0.85 | SMN1; SMN2 (0.69) | KMT2AALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1803272 | 0.83 | CYP4Z1 (0.56) | CYP4F2CYP4A11KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6257338 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11KMT2AALDH1A1GAA | |
| SCHEMBL10456252 | 0.82 | CYP4F2 (0.53) | CYP4F2CYP4A11KMT2AALDH1A1GAA | |
| SCHEMBL10456253 | 0.82 | CYP4F2 (0.53) | CYP4F2CYP4A11KMT2AALDH1A1GAA | |
| SCHEMBL697461 | 0.81 | CYP4F2 (0.50) | CYP4F2CYP4A11KMT2AALDH1A1MAPT | |
| SCHEMBL14606148 | 0.80 | F3 (0.56) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL8784633 | 0.80 | CYP4F2 (0.54) | CYP4F2CYP4A11KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4680336-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| CN-120058611-A | 1-Aryl-5-pyrazolone compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20250145590-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025096539-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250093270-A1 | Method for Detecting Enzyme Activity and Fluorescent Probe Used in Said Method | THE UNIVERSITY OF TOKYO (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4488379-A1 | METHOD FOR DETECTING ENZYME ACTIVITY AND FLUORESCENT PROBE USED IN SAID METHOD | The University of Tokyo (JP) | 2025-01-08 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2005004796-A2 | SULFONYLAMINO PHENYLACETAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CALIXA THERAPEUTICS, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-0874826-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997024331-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-07-10 | — | — | WO | disclosed |
| WO-1995005376-A1 | SUBSTITUTED 2(5H)FURANONE, 2(5H)THIOPHENONE AND 2(5H)PYRROLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1995-02-23 | — | — | WO | disclosed |
| US-4560749-A | ANTIBIOTICS, BACTERICIDES | ELI LILLY AND COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| US-4521598-A | 3-Azidocephalosporins | ELI LILLY AND COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0136177-A2 | 3-Azidocephalosporins as intermediates and novel antibacterial agents | ELI LILLY AND COMPANY (US) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | CYP4F2 4431/4885CYP4A11 3759/4885KMT2A 646/4885 |
| US-20250093270-A1 | Method for Detecting Enzyme Activity and Fluorescent Probe Used in Said Method | ACHE, BCHE, SCLY | CYP4F2 931/4885CYP4A11 2119/4885KMT2A 2133/4885 |
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CYP2E1, CYP2D6, CYP3A43 | CYP4F2 44/4885CYP4A11 49/4885KMT2A 1728/4885 |
| US-20250145590-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | USP1, UBA1, SUMO1 | CYP4F2 3371/4885CYP4A11 846/4885KMT2A 1095/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | CYP4F2 246/4885CYP4A11 113/4885KMT2A 1330/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | CYP4F2 3705/4885CYP4A11 4354/4885KMT2A 2541/4885 |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | CYP4F2 1480/4885CYP4A11 328/4885KMT2A 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.